RxDoctor Payments DataLook up a doctor →

Garland Green, MD

Interventional Cardiology · Baton Rouge, LANPI 1811044795

Payments from drug & device makers

$36,777in general payments, 2019–2025

Across 587 payments — averaging $62.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$13K
  • Boston Scientific$5K
  • Abiomed$4K
  • Edwards Lifesciences$3K
  • Abbott$1K
  • Shockwave Medical, Inc$1K
  • plus $8K from 53 others

What the payments were for

  • Travel & lodging$14,38039%
  • Food & beverage$22,38561%
  • Education$120%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Medtronic(2 entities)78$13,398
Boston Scientific88$4,697
Abiomed51$4,404
Edwards Lifesciences21$3,153
Abbott45$1,439
Shockwave Medical, Inc15$1,403
Philips North America LLC19$689
Amgen20$620
Atricure, Inc.2$466
Pfizer31$460
Novartis33$436
Artivion, Inc.1$398
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)19$386
Johnson & Johnson24$366
Angiodynamics, Inc.7$341
Bard Peripheral Vascular, Inc.3$336
Cardiovascular Systems Inc.4$333
Alnylam Pharmaceuticals Inc.12$324
Inari Medical, Inc.2$274
AstraZeneca(2 entities)12$244
Penumbra, Inc.2$240
Merck15$236
Silk Road Medical, Inc.3$232
Novo Nordisk5$178
Kiniksa Pharmaceuticals, Ltd.2$144
Kestra Medical Technology Services, Inc.5$135
Astellas Pharma US Inc6$132
Boehringer Ingelheim6$128
Scpharmaceuticals Inc.6$100
Acist Medical Systems, Inc.1$98
E.r. Squibb & Sons, L.L.C.7$96
Arbor Pharmaceuticals, Inc.6$83
Smith+Nephew2$81
Lexicon Pharmaceuticals, Inc.4$71
Eko Health, Inc.1$60
Cardiva Medical, Inc.2$54
Cardiac Dimensions, Inc.1$51
Regeneron Healthcare Solutions, Inc.2$37
Sanofi-aventis U.S. LLC2$36
Cvrx, Inc.1$33
Amarin Pharma, Inc.2$27
GE HealthCare1$26
Impulse Dynamics (USA) Inc.1$26
Itamar Medical Inc2$26
Livanova USA, Inc.1$24
United Therapeutics Corporation1$23
Convatec Inc.1$22
Kiniksa Pharmaceuticals International, PLC1$21
Bayer1$21
Daiichi Sankyo Inc.1$20
Esperion Therapeutics, Inc.1$19
Terumo Medical Corporation1$19
Osprey Medical Inc1$18
Actelion Pharmaceuticals US, Inc.1$18
Chiesi USA, Inc.1$18
Acacia Pharma Inc1$16
Tactile Systems Technology Inc1$15
Portola Pharmaceuticals, LLC1$15
Acutus Medical, Inc.1$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$36,777 in reported general payments places this provider in the 70th percentile of 171 interventional cardiology providers in Louisiana.

See all interventional cardiology providers in Louisiana

Medicare billing

Part B allowed, 2024
$444,967
Medicare patients
405
Services billed
4,262

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban384$385,658
EntrestoSacubitril/Valsartan308$382,501
JardianceEmpagliflozin82$93,234
FarxigaDapagliflozin Propanediol68$85,452
Repatha SureclickEvolocumab75$66,374
XareltoRivaroxaban36$48,315
BrilintaTicagrelor55$47,341
OzempicSemaglutide11$19,829
Nebivolol Hcl232$15,390
NexlizetBempedoic Acid/Ezetimibe14$15,296
Atorvastatin Calcium1,267$14,646
Ranolazine ErRanolazine135$13,930
NexletolBempedoic Acid17$13,774
Isosorbide Dinit-HydralazineIsosorbide Dinit/Hydralazine50$12,502
Rosuvastatin Calcium625$8,931

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$460$385,658384 claims
NovartisEntresto$436$382,501308 claims
AstraZenecaFarxiga, Brilinta$244$132,792123 claims
Boehringer IngelheimJardiance$128$93,23482 claims
Johnson & JohnsonXarelto$366$48,31536 claims
Esperion Therapeutics, Inc.Nexlizet, Nexletol$19$29,07031 claims
Novo NordiskOzempic$178$19,82911 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 171 interventional cardiology providers in Louisiana.

Other interventional cardiology in Baton Rouge

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →